Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. PRV Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. PRV Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2026 · first_quarter · Q1
Pharmaceutical issues impacting patients with rare diseases. PRV Reauthorization. Inflation Reduction Act Implementation.
Rare Disease Initiatives. Priority Review Voucher Reauthorization. Affordable Care Act (ACA) Issues and Enhancements. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
PASTEUR Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Rare Disease Initiatives. Newborn Screening. Affordable Care Act (ACA) Issues and Enhancements. Telehealth. H.R.2940/S.1355 - PASTEUR Act of 2023.
PASTEUR Act of 2023
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Rare Disease Initiatives. Newborn Screening. Affordable Care Act (ACA) Issues and Enhancements. Telehealth. H.R.2940/S.1355 - PASTEUR Act of 2023.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · fourth_quarter · Q4
Rare Disease Initiatives. Priority Review Voucher Reauthorization. Newborn Screening. Genetic Testing Access. Affordable Care Act (ACA) Issues and Enhancements. Telehealth.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. PRV Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · third_quarter · Q3
Rare Disease Initiatives. Priority Review Voucher Reauthorization. Newborn Screening.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · second_quarter · 2A
Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Priority Review Voucher Reauthorization. Newborn Screening.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · second_quarter · Q2
Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Priority Review Voucher Reauthorization. Newborn Screening.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2025 · first_quarter · Q1
Rare Disease Initiatives. Affordable Care Act (ACA) Issues and Enhancements. Telehealth. Priority Review Voucher Reauthorization. Accelerated Approval. Newborn Screening.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2023 · third_quarter · Q3
Rare Disease Initiatives. Newborn Screening. Affordable Care Act (ACA) Issues and Enhancements. Telehealth. H.R.2940/S.1355 - PASTEUR Act of 2023.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2023 · second_quarter · Q2
Rare Disease Initiatives. Newborn Screening. Step Therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2023 · first_quarter · Q1
Rare Disease Initiatives. Newborn Screening. Genetic Testing Access. Affordable Care Act (ACA) Issues and Enhancements. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2022 · fourth_quarter · Q4
Rare disease initiatives. Newborn Screening. Genetic Testing Access. Medical Nutrition. Affordable Care Act (ACA) Issues and Enhancements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE